Evonik Expands Lipid-Based Drug Delivery Capabilities with Novel GMP Manufacturing Facility in Vancouver

On August 28, 2026, Evonik announced that it was making an investment of over CAD 150 million to set up a new GMP drug-product manufacturing infrastructure for lipid-based drug delivery in Vancouver, Canada. The expansion will improve its quality control and microbiological testing capabilities for pharmaceutical and biotechnology companies. This project is backed by up to CAD 68 million from the Canadian government’s Strategic Response Fund and is intended to meet the increasing demand for pharmaceutical products based on lipid nanoparticles and liposomes.

This investment will further enhance Vancouver’s life-sciences ecosystem and expand Evonik’s global capabilities in lipid-based drug delivery and in the manufacture of advanced pharmaceuticals. Drug product manufacturing practices are scheduled to start by the end of 2029, and the manufacturing capacity is expected to be more than three times greater than that of Evonik’s current Vancouver facility. Additionally, this strategic move towards developing vaccines, therapeutics and other advanced medicines covers the entire process from development to commercial-scale manufacturing.

Impact on the Biopharmaceuticals Industry

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035.

According to Precedence Research, the expansion might have a major effect on the biopharmaceutical industry by giving it greater access to specialised GMP manufacturing capacity for complex lipid-based drug products. Evonik's extended quality-control and microbiological testing capabilities could contribute to improved manufacturing efficiency and shorter product-release timelines. The facility will probably be of particular value to companies looking for experienced contract development and manufacturing partners in relation to sophisticated drug-delivery technologies.

The lipid nanoparticles are becoming significant for delivering nucleic-acid medicines, such as mRNA-based therapies and vaccines, ensuring more promising candidates move from clinical development into commercialisation without running into immediate production bottlenecks. This initiative could lead to faster development cycles and wider commercialization of advanced therapies.

Impact on the Advanced Therapy Medical Products Industry

The global advanced therapy medicinal products market size was estimated at USD 42.04 billion in 2025 and is predicted to increase from USD 49.11 billion in 2026 to approximately USD 192.67 billion by 2035, expanding at a CAGR of 16.44% from 2026 to 2035.

According to Precedence Research, the increasing demand for innovative treatments means the Vancouver plant would offer superior manufacturing flexibility as new treatments progress from laboratory research through to clinical trials and commercial production. Evonik’s expanded capabilities could thus help such companies gain access to proven expertise in lipid formulation, manufacturing, and scale-up. The increased capacity might meet the growing demand for LNP-based gene therapies, RNA medicines, and other new types of treatments.

The startup biotechnology firms usually have to rely on substantial investments and collaboration, as setting up the necessary specialized GMP facilities on their own can require a large amount of capital and expertise.  Additionally, the project could promote relationships between biotechnology companies, research institutions, and manufacturing specialists and thus help secure Vancouver's position for advanced life-sciences innovation.

Impact on the Pharmaceutical CDMO Industry

The global pharmaceutical CDMO market size is valued at USD 197.40 billion in 2025 and is predicted to increase from USD 211 billion in 2026 to approximately USD 392.67 billion by 2035, expanding at a CAGR of 7.12% from 2026 to 2035.

According to Precedence Research, the move is important for the contract development and manufacturing organization industry, as demand for specialized manufacturing abilities is rising together with the complexity of drug pipelines. The expansion could speed up capacity development in the CDMO market and raise expectations regarding specialized infrastructure, quality systems, and technical proficiency.

By more than tripling its capacity for manufacturing advanced drug products in Vancouver, Evonik could in this way strengthen its competitive edge in lipid-based CDMO services. The pharmaceutical sector targets formulation development, GMP manufacturing, quality control, and support at commercial scale, offering customers a highly integrated route from development through to production. Additionally, competitors might then choose to increase their own investments in lipid nanoparticle and liposome capabilities. 

Expert Opinion

As per expert point of view, Evonik's investment in Vancouver is a strategically vital one because lipid-based delivery is now becoming a crucial in manufacturing method for next-generation medicines and specialised pharmaceutical technology. The most significant advantage could be manufacturing continuity, where developers must have reliable routes that can take complex formulations from early development through to clinical production and commercial scale. 

The fact that the company is deciding to more than triple its existing capacity shows its confidence in the continued demand for LNPs, liposomes and other lipid-based drug products. Government support helps to alleviate part of the investment burden and improves Canada's domestic capabilities in life-sciences manufacturing. The expansion will put Evonik in a dominant position to capitalise on the growing advanced-medicine market and demand for technology platforms to meet regulatory requirements.